Hepatitis B-management of acute infection and active inflammation in pregnancy-a hepatologist's perspective.
Adult
Antiviral Agents
/ therapeutic use
Child
DNA, Viral
Female
Gastroenterologists
/ psychology
Hepatitis B
/ drug therapy
Hepatitis B e Antigens
/ blood
Hepatitis B virus
Humans
Infant
Infectious Disease Transmission, Vertical
/ prevention & control
Inflammation
/ drug therapy
Male
Middle Aged
Pregnancy
Pregnancy Complications, Infectious
/ drug therapy
Telbivudine
/ therapeutic use
Tenofovir
/ therapeutic use
Acute hepatitis
Chronic hepatitis
Hepatitis B virus
Mother-to-child transmission
Pregnancy
Tenofovir disoproxil fumarate
Journal
Best practice & research. Clinical obstetrics & gynaecology
ISSN: 1532-1932
Titre abrégé: Best Pract Res Clin Obstet Gynaecol
Pays: Netherlands
ID NLM: 101121582
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
16
03
2020
revised:
23
03
2020
accepted:
26
03
2020
pubmed:
29
4
2020
medline:
6
11
2020
entrez:
29
4
2020
Statut:
ppublish
Résumé
Women at childbearing age and pregnant ladies living in the areas of high or intermediate prevalence of hepatitis B virus (HBV) remain at risk of getting the infection and passing the infections to their offspring via mother-to-child transmission (MTCT) of HBV. HBV infection may affect the mothers by active hepatitis, very occasionally liver cirrhosis and rarely fulminant hepatitis and liver failure. The virus may be transmitted to the babies despite immunoprophylaxis in the setting of very high maternal viral load. Tenofovir disoproxil fumarate (TDF) has been shown to be efficacious to reduce MTCT of HBV, which contributes to the elimination of chronic HBV infection by 2030, the goal set by World Health Organization.
Identifiants
pubmed: 32340799
pii: S1521-6934(20)30055-9
doi: 10.1016/j.bpobgyn.2020.03.014
pii:
doi:
Substances chimiques
Antiviral Agents
0
DNA, Viral
0
Hepatitis B e Antigens
0
Telbivudine
2OC4HKD3SF
Tenofovir
99YXE507IL
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
54-65Informations de copyright
Copyright © 2020. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Dr. Grace Wong has served as an advisory committee member for Gilead Sciences, as a speaker for Abbott, Abbvie, Bristol-Myers Squibb, Echosens, Furui, Gilead Sciences, Janssen and Roche, and received research grant from Gilead Sciences. Dr. Wan-Hsin Wen declares no competing interests. Dr. Calvin Pan received grants from Gilead. He also serves as a consultant and a speaker for Gilead.